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1. Introduction 
The synthetic tripeptide pyroglutamyl-histidyl- 
prolineamide (TRH) has been shown to possess the 
biological potencies of the natural thyreotropin re- 
leasing factor (TRF) [ 1,2] . This achievement en- 
couraged a large variety of physiological investigations 
and efforts towards the preparation of labelled hor- 
mone. The first attempts reported concerned tritium 
labelling of extractive TRF [3]. The specific radio- 
activity obtained, of the order of 8 mCi/mg was not 
sufficient for precise cellular localisation under phys- 
iological conditions. The simplicity of TRH structure 
suggested a labelling of the molecule by total syn- 
thesis, using labelled amino acids. This aim has been 
reached by Flouret [4] and by Monahan and Young 
[5] using, respectively, 14C-histidine or 3H-proline. 
The specific radioactivities obtained were those of 
the precursor amino acids, 250 mCi/mmole and 50 
Ci/mmole, respectively. 
Previous work had shown that a variety of hor- 
monal peptides could be tritium labelled by catalytic 
replacement of iodine atoms previously bound on 
tyrosyl residues(s) [6,7] . The specific radioactivities 
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were those expected from the number of iodine atoms 
exchanged. The possibilities to separate the iodinated 
peptide either from the non-reacted or from the tri- 
tiated peptide allowed the preparation of biologically 
active labelled material with nearly the theoretical 
specific radioactivities. 
It was gratifying to establish that our technique 
could be used for introducing a tritium atom on a 
histidyl residue belonging to a large peptide, the 
toxin of Naja nigricollis [8] , which contains two 
histidines and a buried tyrosine. This result prompted 
us to investigate the tritium labelling of a short pep 
tide; the present report indicates that two tritium 
atoms could be bound to the histidine side chain of 
TRH with no loss of the biological activity tested. 
2. Experimental 
2.1. Materials 
TRH was kindly provided by Dr. R.O. Studer 
(Hoffman-La Roche, Basel). Halogenation was carried 
out by ICI from Rhone-Poulenc. 1251CI used as tracer 
was from New England Nuclear Corporation. The 
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Table 1 
Release of TSH in rats following injection of 
identical amounts of tritium labelled and standard TRH. 
Amount 
injected 
(ng) 
TSH pU/ml 
Standard TRH 3H-TRH 
50 9.5 f 1.7 8.2 f 1.6 
100 17.4 * 3.3 16.0 i 3.3 
250 25.3 i 5.4 22.5 f 4.5 
500 39 f 7.9 40 i: 8.1 
1000 54.1 f 11.7 63.8 f 11.8 
palladium/A1s03 catalyst was from Engelhardt (Rome). 
The ion exchange resin AC II A8 came from Bio Rad 
Laboratories. The tritium gas was made by the Com- 
missariat a 1’Energie Atomique (France). TRH weight 
determinations were carried out by amino acid mea- 
surement with the Technicon Autoanalyzer. Tritium 
determination was made with SL 30 Intertechnique 
liquid scintillation counter and ‘?odine was counted 
with SAIP-Gammatic solid scintillation device. 
2.2. Preparation of iodo-TRH 
20 @moles 1251CI dissolved in 50 /..d dry methanol 
are slowly (10 set) added to 2.7 pmoles TRH dis- 
solved in 1 ml 0.2 M Na acetate solution pH 6.5, 
chilled to 4”; after 45 set excess Na thiosulfate is 
added. 
2.3. Pllrifcation of iodo-TRH 
The mixture is passed through an AG II A8 column 
(41 X 1.3 cm) to removed the salts. Elution with dis- 
tilled water yielded two peptide peaks. Peak 1 
(5-10%) had the same amino acid composition as 
TRH, and contained no iodine. Peak II (85--90%) 
corresponded to halogenated material. Thin-layer 
chromatography on cellulose (acetone:water, 80:40) 
of peak II indicated a trace of a non-halogenated com- 
pound beside iodo-TRH. 
2.4. Tritiation 
Peak II was flash evaporated and redissolved into 
500 ~10.1 M phosphate buffer pH 7.3 . 10 mg 
Pd/Als03 catalyst were added to the cup of the triti-i 
ation flask containing the iodo-TRH. The latter was 
frozen and connected to the vacuum line. After 10e4 
Torr were reached, 10 Ci 99% pure tritium gas were 
introduced (pressure 200 Torr) flushing the Pd cata- 
lyst which was afterwards dropped into the frozen 
solution. Gradual melting was allowed. After 20 min 
the catalyst was removed by Millipore filtration and 
the labile hydrogens exchanged by successive flash 
evaporation. 
2.5. Purification 
The 3H-TRH soltuion was filtered on an AG II A8 
column, and the peptide eluted with distilled water. 
Two peaks were found. The first represented 3H-TRH 
as shown by thin-layer co-chromatography with con- 
trol substance on silica gel (CHC13-CH30H- cont. 
IV&OH, 60/45/20). The UV spectrum of the 3H-TRH 
was not different from the control. After acid hydro- 
lysis of an aliquot of the labelled compound (6 N 
HCl, 1 lo”, 16 hr) the three constitutive amino acids 
were found. Their quantitative estimation indicated 
a total amount of 120 pg 3H-TRH. On that basis the 
specific radioactivity was found to be 60 Ciimmole. 
2.6. Biological tests 
To check that the labelled compound (3H-TRH) 
obtained was biologically active two assays were per- 
Table 2 
Action of cold and tritiated TRH on the prolactin released in the media by GH3 
cells, after 48 hr of contact (ng of prolactin per ml). 
Nature 
of the 
TRH 0.1 
TRH doses (&ml) 
1 10 
Control 
TRH 67.3 f 4.6* 60.6 f 2.4* 97.3 5 53.7 f 
3H-TRH 
4.6* 3.5** 
62.0 f 5.0* 82.6 f 4.8* 92.6 i 4.0* 57.3 f 1.2** 
*Average of 3 wells by dose. **Average of 9 control wells. 
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formed: the release of TSH and the release of prolac- 
tin. 
2.6.1. Release of TSH in the rat 
Increasing amounts of 3H-labelled and control 
TRH were dissolved into 0.5 ml of isotonic NaCl sol- 
ution, injected intraperitoneally into 200-250 g 
Wistar rats anesthetized by Nembutal(4 mg/lOO g). 
Right animals were used for each dose. 0.5 ml of 
blood were withdrawn after 15 and 30 min and the 
TSH concentration estimated by radioimmunoassay 
[9-l 11. The TSH base line for control animals was 
the mean value of the levels found at 15 and 30 min. 
The figure found for Nembutal anesthetized rats was 
3 f 0.8 pU/ml, with extreme at 1 and 10.5 pU/ml. As 
shown in table 1 equal doses of 3H-TRH and control 
TRH released the same mean amounts of TSH. 
2.6.2. Release of prolactin 
The response to TRH of GH3 clonal strain (rat pro- 
lactin cells [ 121) has been previously established [ 13, 
141. Cells from this clone were plated in 6 “disposo 
trays” (Linbro FB6-TC) at the density of 2.5 X lo4 
cells/well, in 2 ml medium (medium HAM F 10 + 15% 
horse serum + 2.5% foetal calf serum). After 48 hr the 
medium was changed and the TRH introduced at 3 
different doses: 0.1, 1 and 10 &ml. Each tray con- 
tained 3 treated wells and 3 control wells. For each 
dose of cold or 3H-TRH, we used a separate tray. A 
new dose of TRF was added after 24 hr. The prolac- 
tin concentration in the medium after 24 hr and 48 
hr of contact with the TRH was measured with a 
radioimmunoassay using the NIAMD kit for rat pro- 
lactin [ 15 ] (minimum detectable amount: 10 pico- 
gram). The stimulation of the prolactin production 
was evident after 48 hr of contact and reached the 
same level with cold as well as with labelled TRF 
(table 2). In addition to their biological responsive- 
ness to the tritiated TRF, the GH3 cells possess the 
ability to selectively bind this molecule (manuscript 
in preparation). 
3. Discussion 
The analytical characteristics as well as the biolog- 
ical potencies of the 3H-TRH indicated that the label- 
led peptide was indistinguishable from the original 
material. Thus the labelling technique used seems to 
be valuable for the rapid preparation of 3H-TRH. The 
specific radioactivity reached, 60 Ci/mmole, corres- 
ponded to the replacement of 2 H by 2 tritium atoms 
per mole in positions 2 and 4 of the imidazole side 
chain. 
As well as those obtained with the 3H-proline la; 
belled peptide made by Monahan and Young (5), it 
is indicated that even in a short peptide devoid of a 
large variety of side chains, substitution of 2 H by 2 
tritium atoms on two essential rings, did not modify 
the ability of the peptide to bind and to trigger the 
biological responses investigated. It is thus demon- 
strated that tritium labelling of substance acting by 
virtue of their structure apparently leads to com- 
pounds as close as possible to their non-labelled 
counterpart. 
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